Stock Ratings / Health Care / RGC / earnings

DFTX (52) TRLV (58) CRON (52) TLRY (32) ⌘ Pro Terminal →

Regencell Bioscience Holdings Limited (RGC) Next Earnings Date & Expected ±12.5% Move

$6.86 -5.64% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Regencell Bioscience Holdings Limited (RGC) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $3.40B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RGC)Realized 20D OHLCV Swing Band: ±12.5%

NEXT EST. WINDOW: Dec 28, 2026 (~56 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.86 Expected Swing

MODEL EARNINGS SETUP GAUGE

RGC Quantitative Pre-Earnings Setup: 38/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (38/100)Model Risk Weight (62/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-06-30	$0	-$3.6M	-$3.3M	52%
FY 2024	2024-06-30	$0	-$4.3M	-$4.0M	52%
FY 2023	2023-06-30	$0	-$5.9M	-$5.0M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RGC)

✓Walkthrough of RGC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

RGC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -76.52%🛡️ HOLDING TREND SUPPORT

2026-10-30O $6.89H $7.05L $6.53C $6.86VOL 147.7K

RES: $12.07SUP: $6.62SMA50: $6.83SMA200: $17.15

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RGC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RGC Butterfly Map → + Track RGC →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on RGC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RGC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for RGC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RGC)

Health Care Rank #695 of 1016 ⚔️ DFTX vs RGC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RGC vs. DFTX, TRLV, CRON, TLRY)

Industry: Medicinal Chemicals and Botanical Products (24 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Regencell Bioscience Holdings Limited (RGC) ranks #695 by composite RQD confidence (38/100, grade D-) and #195 by equity capitalization ($3.40B). Within this direct 5-issuer industry benchmark cohort, RGC leads on earnings valuation at N/A trailing P/E, while TRLV leads on capital efficiency and profitability with 12.8% ROIC and 60.2% gross margin. TRLV currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with RGC at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
RGC ACTIVE Regencell Bioscience Holdings Limited	D-	38/100	—	—	—	-5.64%	$3.40B	Benchmark Subject
DFTX Definium Therapeutics Inc.	D+	52/100	—	—	-32.2%	-0.37%	$5.10B	/dftx-vs-rgc →
TRLV Trulieve Cannabis Corp. Subordinate Voting Shares	D+	58/100	—	60.2%	12.8%	-0.19%	$2.04B	/trlv-vs-rgc →
CRON Cronos Group Inc. Common Share	D+	52/100	—	42.8%	-4.5%	+0.30%	$1.24B	/cron-vs-rgc →
TLRY Tilray Brands Inc.	E	32/100	—	28.4%	-3.9%	-1.86%	$390.2M	/tlry-vs-rgc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001829667

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Regencell Bioscience Holdings Limited (RGC) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$3.6M, operating cash flow of -$3.1M, and free cash flow of -$3.3M (+18.5% YoY). On the balance sheet, RGC closed FY2025 with $0 in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-06-30	$0	-$3.6M	-$3.1M	-$3.3M	—	—
FY2024 (FY)	2024-06-30	$0	-$4.3M	-$4.0M	-$4.0M	—	—
FY2023 (FY)	2023-06-30	$0	-$5.9M	-$5.0M	-$5.0M	—	—

3. RGC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RGC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Regencell Bioscience Holdings Limited (NASDAQ: RGC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $6.86 (-5.64% 1D, market cap $3.40B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, RGC ranks #695 in composite RQD confidence.

How does RGC compare to DFTX and TRLV in the Health Care sector?

Within the Health Care sector (Medicinal Chemicals and Botanical Products), RGC carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, DFTX (Definium Therapeutics Inc.) holds a D+ grade (52/100 RQD, P/E N/A, ROIC -32.2%, cap $5.10B) and TRLV (Trulieve Cannabis Corp. Subordinate Voting Shares) posts a D+ grade (58/100 RQD, P/E N/A, ROIC 12.8%, cap $2.04B). Among the 5-stock peer group, RGC leads on earnings multiple (N/A) while TRLV leads on capital efficiency (12.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RGC?

Per RGC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001829667), Regencell Bioscience Holdings Limited generated $0 in revenue, -$3.6M in net income, and -$3.3M in free cash flow against $0 in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RGC trading relative to its 50-day, 200-day, and 52-week technical levels?

RGC last traded at $6.86 (-5.64% on volume of 183,670 shares), positioning the stock +0.44% above its 50-day simple moving average ($6.83) and -60.00% below its 200-day simple moving average ($17.15). Across its 52-week range of $4.51 to $69.00, RGC sits at the 3.6% percentile with a 14-day RSI of 42.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($6.00 to $7.72).